-
Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page
One Ms really?
- Thread starter anonymous
- Start date
-
- Tags
- None
I think most of us are that came here now with several reps and managers covering same areas and some territories nationally are underperforming with not even 10 sf’s!!!! Access is still difficult but sales must increase
Wonder how many are looking to leave after march payout? Hmm...
Aimovig team gone as of today. Merger of S1P and Kesimpta team coming next. Portfolio rep will carry all products.
The ms side changes will more then likely happen at the end of the year with realignments. Won’t be the entire division eliminated and as people leave, etc positions are not being filled which will help. This RIF was due to ongoing lawsuit from 2+ yrs old.
Aren't all lawsuits settled? Didn't the chairman for Novartis just come out and say that behavior won't happen again?
Lawsuits can take years for a settlement with litigation or even mediation which is what has happened with Amgen.
They expanded Neuroscience MSLs prior to letting everyone go. There will be a merger of teams with people being let go by end of year latest.
Better start doing some major a** kissing. Novartis adores these people and promotes them readily. The better you are at it, the further you'll go.
The only vacancies being filled for the next 90 days is with internal/Aimovig folks across all divisions—oncology, derm, CRM, etc. Can anyone confirm the MSL’s they hired for the expansion were the ones let go?
I do think a realignment is going to happen on the MS side=86 S1P reps, 100+ K reps, 26 ABL’s, (7 AM’s, 7 TLL’s, 2 RD’S over those) 4 RD’S, and 2 VP’s for the field. This does not count HQ (training,etc)
10 MSLs and 3 of the leadership were let go. Some MSLs that only supported MS were let go in favor of migraine-supporting MSLs with lesser tenure that were hired as part of the expansion.